Literature DB >> 29791907

Toll-Like Receptor 3 Signaling Contributes to Regional Neutrophil Recruitment in Cultured Human Glomerular Endothelial Cells.

Qiang Liu1,2, Tadaatsu Imaizumi3, Shogo Kawaguchi4, Tomomi Aizawa5, Tomoh Matsumiya3, Shojiro Watanabe5, Koji Tsugawa5, Hidemi Yoshida3, Kazushi Tsuruga5, Kensuke Joh6, Hiroshi Kijima1, Hiroshi Tanaka1,7.   

Abstract

BACKGROUND: Given the importance of neutrophil recruitment in the pathogenesis of glomerulonephritis (GN), the representative neutrophil chemoattractant C-X-C motif chemokine 1 (CXCL1)/GROα and the adhesion molecule E-selectin in glomerular endothelial cells (GECs) play a pivotal role in the development of GN. Endothelial Toll-like receptor 3 (TLR3) is thought to be involved in the inflammatory response via innate immunity. However, the role of endothelial TLR3 signaling in the expression of neutrophil chemoattractants and adhesion molecules remains to be elucidated. Thus, we aimed to examine this issue.
METHODS: We treated normal human GECs with polyinosinic-polycytidylic acid (poly IC), an authentic double-stranded RNA, and analyzed the expressions of CXCL1 and E-selectin using quantitative real-time reverse transcription-polymerase chain reaction, western blotting, and enzyme-linked immunosorbent assay. To further elucidate the poly IC-induced signaling pathway, we subjected the cells to RNA interference against TLR3, interferon (IFN)-β, nuclear factor (NF)-κB p65, and IFN regulatory factor (IRF) 3. We also used immunofluorescence to examine the endothelial expression of CXCL1 in biopsy specimens from patients with crescentic and non-crescentic purpura nephritis (PN).
RESULTS: We found that the activation of TLR3 induced the endothelial expression of CXCL1 and E-selectin, and that this involved TLR3, -NF-κB, IRF3, and IFN-β. Intense endothelial CXCL1 expression was observed in biopsy specimens from patients with crescentic PN.
CONCLUSION: These findings support a role for glomerular antiviral innate immunity in the pathogenesis of GN. Intervention of glomerular TLR3 signaling may therefore be a suitable therapeutic strategy for treating GN in the future.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  CXCL1; E-selectin; Human glomerular endothelial cells; Neutrophil recruitment; Purpura nephritis; Toll-like receptor 3

Mesh:

Substances:

Year:  2018        PMID: 29791907     DOI: 10.1159/000489507

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  4 in total

1.  Inhibitory effect of anti-malarial agents on the expression of proinflammatory chemokines via Toll-like receptor 3 signaling in human glomerular endothelial cells.

Authors:  Riko Sato; Tadaatsu Imaizumi; Tomomi Aizawa; Shojiro Watanabe; Koji Tsugawa; Shogo Kawaguchi; Kazuhiko Seya; Tomoh Matsumiya; Hiroshi Tanaka
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

2.  Neutrophil extracellular traps impair regeneration.

Authors:  Eric Wier; Mayumi Asada; Gaofeng Wang; Martin P Alphonse; Ang Li; Chase Hintelmann; Evan Sweren; Christine Youn; Brittany Pielstick; Roger Ortines; Chenyi Lyu; Maria Daskam; Lloyd S Miller; Nathan K Archer; Luis A Garza
Journal:  J Cell Mol Med       Date:  2021-10-08       Impact factor: 5.310

3.  Exploring the Underlying Mechanism of Shenyankangfu Tablet in the Treatment of Glomerulonephritis Through Network Pharmacology, Machine Learning, Molecular Docking, and Experimental Validation.

Authors:  Meiling Jin; Wenwen Ren; Weiguang Zhang; Linchang Liu; Zhiwei Yin; Diangeng Li
Journal:  Drug Des Devel Ther       Date:  2021-11-09       Impact factor: 4.162

4.  Glomerular endothelial expression of type I IFN-stimulated gene, DExD/H-Box helicase 60 via toll-like receptor 3 signaling: possible involvement in the pathogenesis of lupus nephritis.

Authors:  Takao Karasawa; Riko Sato; Tadaatsu Imaizumi; Shun Hashimoto; Masashi Fujita; Tomomi Aizawa; Koji Tsugawa; Shogo Kawaguchi; Kazuhiko Seya; Kiminori Terui; Hiroshi Tanaka
Journal:  Ren Fail       Date:  2022-12       Impact factor: 2.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.